ITGB4 (Integrin beta-4) variants and mutations
ITGB4 (also known as Integrin beta-4) is a human protein-coding gene encoding an integrin beta-4 protein. It pairs with alpha6 integrin in hemidesmosomes to anchor epithelial cells to laminin-rich basement membranes. Biallelic loss-of-function variants can cause junctional epidermolysis bullosa with pyloric atresia and severe epithelial fragility. This analysis covers 2,379 ITGB4 variants and mutations. Of these, 77% have computational variant effect predictions. Disease context includes junctional epidermolysis bullosa with pyloric atresia, Junctional epidermolysis bullosa - pyloric atresia, and epidermolysis bullosa, junctional 5A, intermediate. Example ITGB4 variants include A2V, A2S, and G3R.
Variant analysis overview
- Gene: ITGB4
- Protein: Integrin beta-4
- UniProt accession: P16144
- Organism: Homo sapiens
- Variants analyzed: 2379
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 2,221 unspecified-consequence records; 75 missense variants; 71 synonymous variants; 6 frameshift variants; 2 splice-region variants; 2 in-frame deletions; 2 stop-gained variants; 3 substitution
- Prediction scores: 1,841 variants have prediction scores (77% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: junctional epidermolysis bullosa with pyloric atresia, Junctional epidermolysis bullosa - pyloric atresia, epidermolysis bullosa, junctional 5A, intermediate, Generalized junctional epidermolysis bullosa, non-Herlitz type, junctional epidermolysis bullosa, non-Herlitz type, localized junctional epidermolysis bullosa, non-Herlitz type, junctional epidermolysis bullosa, junctional epidermolysis bullosa inversa, generalized junctional epidermolysis bullosa non-Herlitz type, Localized epidermolysis bullosa simplex, epidermolysis bullosa simplex 1C, localized, multiple sclerosis.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 11 domains; 12 binding sites; 15 post-translational modification sites.
- Structural context: 1,155 variants have structural context.
- PTM context: 14 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable ITGB4 variants
Examples include A2V, A2S, G3R, P4A, P4L, P4S, P4T, R5C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2V (p.Ala2Val), Ensembl rs1568339518, REVEL 0.19, CADD 25.00
- A2S (p.Ala2Ser), gnomAD 17-75724707-G-T, REVEL 0.23, CADD 25.70
- G3R (p.Gly3Arg), cosmic curated COSV52329, ESP rs142907560, TOPMed rs142907560, REVEL 0.07, CADD 23.10
- P4A (p.Pro4Ala), 1000Genomes rs567076241, ExAC rs567076241, TOPMed rs567076241, gnomAD rs567076241, Uncertain significance
- P4L (p.Pro4Leu), 1000Genomes rs147285287, ESP rs147285287, gnomAD rs147285287, REVEL 0.13, CADD 9.47
- P4S (p.Pro4Ser), rs567076241, ClinGen CA8768511, ClinVar RCV002508494, ClinVar RCV005019221, REVEL 0.12, CADD 22.80, Uncertain significance, Inborn genetic diseases; Junctional epidermolysis bullosa with pyloric atresia
- P4T (p.Pro4Thr), gnomAD 17-75724713-C-A, REVEL 0.13, CADD 22.30
- R5C (p.Arg5Cys), rs141077392, ESP rs141077392, ExAC rs141077392, TOPMed rs141077392, REVEL 0.12, CADD 0.47, Variant assessed as somatic; moderate impact.
- R5H (p.Arg5His), rs374855840, ClinGen CA8768513, cosmic curated COSV52325, ClinVar RCV002999248, REVEL 0.08, CADD 0.72, Conflicting interpretations, not provided; Epidermolysis bullosa, junctional 5A, intermediate; Junctional epi
- R5S (p.Arg5Ser), ESP rs141077392, ExAC rs141077392, TOPMed rs141077392, gnomAD rs141077392, REVEL 0.05, CADD 0.04
- R5L (p.Arg5Leu), gnomAD 17-75724717-G-T, REVEL 0.07, CADD 1.00
- R5R (p.Arg5Arg), rs775898450, gnomAD 17-75724718-C-T, CADD 3.67
- P6S (p.Pro6Ser), ExAC rs747230853, TOPMed rs747230853, gnomAD rs747230853, REVEL 0.07, CADD 8.41, Uncertain significance, Inborn genetic diseases
- P6T (p.Pro6Thr), ExAC rs747230853, TOPMed rs747230853, gnomAD rs747230853, REVEL 0.13, CADD 12.90, Uncertain significance, Inborn genetic diseases
- P6R (p.Pro6Arg), gnomAD 17-75724720-C-G, REVEL 0.16, CADD 15.70
- P6P (p.Pro6Pro), rs768734852, gnomAD 17-75724721-C-T, CADD 9.25
- S7R (p.Ser7Arg), NCI-TCGA Cosmic COSV9956, cosmic curated COSV99564, Variant assessed as somatic; moderate impact.
- S7S (p.Ser7Ser), rs368149213, gnomAD 17-75724724-C-T, CADD 7.45
- P8L (p.Pro8Leu), TOPMed rs1180093286, gnomAD rs1180093286, REVEL 0.05, CADD 4.22
- P8T (p.Pro8Thr), gnomAD 17-75724725-C-A, REVEL 0.09, CADD 15.60
- P8S (p.Pro8Ser), gnomAD 17-75724725-C-T, REVEL 0.07, CADD 15.90
- P8P (p.Pro8Pro), rs2148452006, gnomAD 17-75724727-A-G, CADD 1.38
- W9* (p.Trp9Ter), rs2545709621, ClinGen CA401062671, ClinVar RCV003544088, Pathogenic
- W9C (p.Trp9Cys), Ensembl rs1599207972
- A10S (p.Ala10Ser), gnomAD rs2060684197, REVEL 0.08, CADD 14.30
- L12L (p.Leu12Leu), rs934665221, gnomAD 17-75724737-C-T, CADD 12.20
- L13L (p.Leu13Leu), gnomAD 17-75724742-C-G, CADD 8.36
- L14R (p.Leu14Arg), TOPMed rs2060684376
- L14L (p.Leu14Leu), gnomAD 17-75724745-G-A, CADD 11.30
- A15T (p.Ala15Thr), rs560574772, ClinGen CA8768518, ClinVar RCV002594830, ClinVar RCV005655020, REVEL 0.13, CADD 20.20, Conflicting interpretations, Inborn genetic diseases; not provided
- A15V (p.Ala15Val), ExAC rs765798295, gnomAD rs765798295, REVEL 0.03, CADD 11.30
- A15E (p.Ala15Glu), gnomAD 17-75724747-C-A, REVEL 0.21, CADD 12.40
- A16G (p.Ala16Gly), ExAC rs773548728, TOPMed rs773548728, gnomAD rs773548728, REVEL 0.11, CADD 15.30
- A16V (p.Ala16Val), ExAC rs773548728, TOPMed rs773548728, gnomAD rs773548728, REVEL 0.07, CADD 14.30
- A16D (p.Ala16Asp), gnomAD 17-75724750-C-A, REVEL 0.35, CADD 18.60
- L17F (p.Leu17Phe), NCI-TCGA Cosmic COSV5232, cosmic curated COSV52324, TOPMed rs2060684696, gnomAD rs2060684696, REVEL 0.15, CADD 17.00, Variant assessed as somatic; moderate impact.
- L17L (p.Leu17Leu), rs763352982, gnomAD 17-75724752-T-C, CADD 6.00
- I18F (p.Ile18Phe), TOPMed rs1465612592
- I18N (p.Ile18Asn), gnomAD rs1269355588, REVEL 0.35, CADD 23.30
- I18V (p.Ile18Val), gnomAD 17-75724755-A-G, REVEL 0.10, CADD 13.60
- S19I (p.Ser19Ile), gnomAD 17-75724759-G-T, REVEL 0.20, CADD 18.00
- S19S (p.Ser19Ser), rs145773550, gnomAD 17-75724760-C-T, CADD 4.07
- V20A (p.Val20Ala), TOPMed rs947482911, REVEL 0.12, CADD 0.17
- V20I (p.Val20Ile), rs751173051, ExAC rs751173051, TOPMed rs751173051, gnomAD rs751173051, REVEL 0.07, CADD 0.36, Uncertain significance, Epidermolysis bullosa, junctional 5A, intermediate; Junctional epidermolysis bul
- V20L (p.Val20Leu), ExAC rs751173051, TOPMed rs751173051, gnomAD rs751173051, REVEL 0.07, CADD 0.33, Uncertain significance
- V20V (p.Val20Val), rs1270723033, gnomAD 17-75724763-C-T, CADD 8.20
- S21G (p.Ser21Gly), gnomAD 17-75724764-A-G, REVEL 0.05, CADD 11.80
- L22V (p.Leu22Val), gnomAD 17-75724767-C-G, REVEL 0.07, CADD 1.41
- L22L (p.Leu22Leu), gnomAD 17-75724769-C-T, CADD 6.24
- S23F (p.Ser23Phe), TOPMed rs1453010120, gnomAD rs1453010120, REVEL 0.13, CADD 15.70
- S23S (p.Ser23Ser), rs893157925, gnomAD 17-75724772-T-C, CADD 4.92
- G24W (p.Gly24Trp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G24R (p.Gly24Arg), gnomAD 17-75724773-G-A, REVEL 0.48, CADD 26.50
- G24G (p.Gly24Gly), gnomAD 17-75724775-G-C, CADD 6.76
- T25A (p.Thr25Ala), gnomAD 17-75724776-A-G, REVEL 0.08, CADD 1.62
- T25T (p.Thr25Thr), rs1199105103, gnomAD 17-75724778-C-T, CADD 9.16
- L26L (p.Leu26Leu), gnomAD 17-75724779-T-C, CADD 9.04
- A27T (p.Ala27Thr), gnomAD 17-75724782-G-A, REVEL 0.24, CADD 32.00
- R29C (p.Arg29Cys), rs138695324, ClinGen CA8768538, ClinVar RCV002747332, ClinVar RCV005021683, REVEL 0.54, CADD 26.70, Uncertain significance, Epidermolysis bullosa, junctional 5A, intermediate; Junctional epidermolysis bul
- R29H (p.Arg29His), 1000Genomes rs530665868, ExAC rs530665868, TOPMed rs530665868, gnomAD rs530665868, REVEL 0.32, CADD 19.10, Uncertain significance, Epidermolysis bullosa, junctional 5A, intermediate; Junctional epidermolysis bul
- R29L (p.Arg29Leu), 1000Genomes rs530665868, ExAC rs530665868, TOPMed rs530665868, gnomAD rs530665868, REVEL 0.46, CADD 22.50, Uncertain significance
- R29S (p.Arg29Ser), cosmic curated COSV10456, ESP rs138695324, ExAC rs138695324, TOPMed rs138695324, REVEL 0.38, CADD 23.20, Uncertain significance
- C30R (p.Cys30Arg), TOPMed rs1328578813, gnomAD rs1328578813, REVEL 0.86, CADD 27.30
- C30Y (p.Cys30Tyr), TOPMed rs2060736949, gnomAD rs2060736949, REVEL 0.86, CADD 26.90
- C30* (p.Cys30Ter), rs2148461288, gnomAD 17-75727203-TGCAA, CADD 32.00
- K31E (p.Lys31Glu), TOPMed rs1455924041, gnomAD rs1455924041, REVEL 0.26, CADD 19.80
- K31N (p.Lys31Asn), rs2060737043, ClinGen CA401037706, ClinVar RCV001122207, Ensembl rs2060737043, Uncertain significance, Junctional epidermolysis bullosa with pyloric atresia
- A33S (p.Ala33Ser), TOPMed rs745322866, gnomAD rs745322866, REVEL 0.12, CADD 18.30, Uncertain significance
- A33T (p.Ala33Thr), rs745322866, ClinGen CA294057871, ClinVar RCV003371770, TOPMed rs745322866, REVEL 0.18, CADD 22.10, Uncertain significance, Inborn genetic diseases
- A33V (p.Ala33Val), gnomAD rs1244895385, REVEL 0.28, CADD 22.70
- A33D (p.Ala33Asp), gnomAD 17-75727213-C-A, REVEL 0.38, CADD 22.90
- A33A (p.Ala33Ala), rs1269062146, gnomAD 17-75727214-C-T, CADD 7.77
- P34L (p.Pro34Leu), ExAC rs774591158, gnomAD rs774591158, REVEL 0.14, CADD 19.30
- P34P (p.Pro34Pro), gnomAD 17-75727217-A-G, CADD 13.50
- V35L (p.Val35Leu), ExAC rs759223935, gnomAD rs759223935, REVEL 0.43, CADD 23.90, Uncertain significance, Inborn genetic diseases
- V35M (p.Val35Met), gnomAD 17-75727218-G-A, REVEL 0.56, CADD 26.40
- V35A (p.Val35Ala), gnomAD 17-75727219-T-C, REVEL 0.16, CADD 18.00
- K36R (p.Lys36Arg), rs2060737432, gnomAD 17-75727220-GA-G, CADD 32.00
- K36T (p.Lys36Thr), gnomAD 17-75727222-A-C, REVEL 0.19, CADD 22.30
- S37G (p.Ser37Gly), NCI-TCGA TCGA novel, REVEL 0.81, CADD 26.90, Variant assessed as somatic; moderate impact.
- S37I (p.Ser37Ile), rs972322019, ClinGen CA401037798, ClinVar RCV003266896, TOPMed rs972322019, REVEL 0.85, CADD 25.20, Uncertain significance, Inborn genetic diseases
- S37N (p.Ser37Asn), TOPMed rs972322019, REVEL 0.38, CADD 21.40, Uncertain significance
- S37C (p.Ser37Cys), gnomAD 17-75727224-A-T, REVEL 0.92, CADD 26.80
- S37S (p.Ser37Ser), rs767136048, gnomAD 17-75727226-C-T, CADD 14.20
- S37R (p.Ser37Arg), gnomAD 17-75727226-C-G, REVEL 0.79, CADD 25.50
- C38F (p.Cys38Phe), ExAC rs752230205, TOPMed rs752230205, gnomAD rs752230205, REVEL 0.98, CADD 29.80
- C38R (p.Cys38Arg), rs121912465, ClinGen CA257307, ClinVar RCV000015859, UniProt VAR 010652, REVEL 0.98, CADD 29.90, Pathogenic, Junctional epidermolysis bullosa with pyloric atresia
- C38C (p.Cys38Cys), rs1198478947, gnomAD 17-75727229-C-T, CADD 11.60
- T39M (p.Thr39Met), cosmic curated COSV52322, ESP rs372947104, TOPMed rs372947104, gnomAD rs372947104, REVEL 0.56, CADD 26.20
- T39T (p.Thr39Thr), rs760303034, gnomAD 17-75727232-G-A, CADD 2.59
- E40D (p.Glu40Asp), rs753782989, NCI-TCGA Cosmic COSV5232, cosmic curated COSV52328, ExAC rs753782989, REVEL 0.50, CADD 23.50, Variant assessed as somatic; moderate impact.
- E40G (p.Glu40Gly), ExAC rs763732398, TOPMed rs763732398, gnomAD rs763732398, REVEL 0.76, CADD 32.00, Uncertain significance, Epidermolysis bullosa, junctional 5A, intermediate; Junctional epidermolysis bul
- E40E (p.Glu40Glu), gnomAD 17-75727235-G-A, CADD 12.10
- C41G (p.Cys41Gly), gnomAD rs920810686
- C41R (p.Cys41Arg), gnomAD rs920810686, REVEL 0.98, CADD 31.00
- C41Y (p.Cys41Tyr), TOPMed rs2060738080, gnomAD rs2060738080
- V42I (p.Val42Ile), cosmic curated COSV52321, Ensembl rs1568342331, REVEL 0.18, CADD 13.70
- V42F (p.Val42Phe), gnomAD 17-75727239-G-T, REVEL 0.51, CADD 22.50
- V42L (p.Val42Leu), gnomAD 17-75727239-G-C, REVEL 0.22, CADD 17.00
- R43C (p.Arg43Cys), cosmic curated COSV10585, ExAC rs757276151, TOPMed rs757276151, gnomAD rs757276151, REVEL 0.79, CADD 32.00
- R43G (p.Arg43Gly), ExAC rs757276151, TOPMed rs757276151, gnomAD rs757276151, REVEL 0.80, CADD 28.20, Uncertain significance, not provided
- R43H (p.Arg43His), rs778748791, NCI-TCGA Cosmic COSV5232, cosmic curated COSV52324, ExAC rs778748791, REVEL 0.70, CADD 31.00, Variant assessed as somatic; moderate impact.
- R43L (p.Arg43Leu), NCI-TCGA Cosmic COSV5232, REVEL 0.67, CADD 26.20, Variant assessed as somatic; moderate impact.
- R43P (p.Arg43Pro), ExAC rs778748791, gnomAD rs778748791, REVEL 0.79, CADD 32.00
- V44V (p.Val44Val), gnomAD 17-75727247-G-C, CADD 13.10
- D45G (p.Asp45Gly), TOPMed rs1254788907, gnomAD rs1254788907, REVEL 0.17, CADD 22.90
- D45H (p.Asp45His), ExAC rs750249253, TOPMed rs750249253, gnomAD rs750249253, REVEL 0.34, CADD 24.40
- K46E (p.Lys46Glu), ExAC rs755212864, TOPMed rs755212864, gnomAD rs755212864, REVEL 0.41, CADD 23.30, Uncertain significance, Inborn genetic diseases
- K46K (p.Lys46Lys), rs781314847, gnomAD 17-75727253-G-A, CADD 11.70
- K46N (p.Lys46Asn), gnomAD 17-75727253-G-C, REVEL 0.62, CADD 25.30
- D47N (p.Asp47Asn), gnomAD rs1403608717, REVEL 0.28, CADD 23.70, Uncertain significance, Inborn genetic diseases
- D47H (p.Asp47His), gnomAD 17-75727254-G-C, REVEL 0.53, CADD 24.40
- D47V (p.Asp47Val), gnomAD 17-75727255-A-T, REVEL 0.76, CADD 26.80
- C48R (p.Cys48Arg), TOPMed rs1487542096, REVEL 0.98, CADD 29.80
- C48W (p.Cys48Trp), gnomAD 17-75727259-C-G, REVEL 0.83, CADD 16.40
- C48C (p.Cys48Cys), rs150023264, gnomAD 17-75727259-C-T, CADD 3.89
- A49S (p.Ala49Ser), rs146966502, NCI-TCGA Cosmic COSV5233, cosmic curated COSV52331, 1000Genomes rs146966502, REVEL 0.41, CADD 23.90, Uncertain significance
- A49T (p.Ala49Thr), rs146966502, cosmic curated COSV52324, NCI-TCGA Cosmic COSV5233, 1000Genomes rs146966502, REVEL 0.63, CADD 27.80, Uncertain significance, Epidermolysis bullosa, junctional 5A, intermediate; Junctional epidermolysis bul
- A49A (p.Ala49Ala), gnomAD 17-75727262-C-G, CADD 13.00
- Y50C (p.Tyr50Cys), gnomAD 17-75727264-A-G, REVEL 0.90, CADD 29.60
- Y50Y (p.Tyr50Tyr), gnomAD 17-75727265-C-T, CADD 10.70
- C51R (p.Cys51Arg), ExAC rs749736808, TOPMed rs749736808, gnomAD rs749736808, REVEL 0.97, CADD 31.00
- C51S (p.Cys51Ser), ExAC rs749736808, TOPMed rs749736808, gnomAD rs749736808, REVEL 0.94, CADD 28.20
- T52A (p.Thr52Ala), NCI-TCGA Cosmic COSV9956, cosmic curated COSV99564, Variant assessed as somatic; moderate impact.
- T52R (p.Thr52Arg), TOPMed rs2060739020
- T52T (p.Thr52Thr), gnomAD 17-75727271-A-G, CADD 0.54
- D53D (p.Asp53Asp), rs774764615, gnomAD 17-75727274-C-T, CADD 2.20
- E54K (p.Glu54Lys), rs759870083, ExAC rs759870083, TOPMed rs759870083, gnomAD rs759870083, REVEL 0.61, CADD 23.70, Variant assessed as somatic; moderate impact.
- E54E (p.Glu54Glu), rs2060739187, gnomAD 17-75727277-G-A, CADD 24.10
- M55I (p.Met55Ile), Ensembl rs2148462610, Uncertain significance, Inborn genetic diseases
- M55L (p.Met55Leu), Ensembl rs2148462580
- M55T (p.Met55Thr), gnomAD rs1223817805, REVEL 0.26, CADD 12.60
- F56C (p.Phe56Cys), TOPMed rs1414942059, gnomAD rs1414942059, REVEL 0.93, CADD 25.30
- F56L (p.Phe56Leu), ExAC rs764349772, gnomAD rs764349772, REVEL 0.77, CADD 23.70
- R57G (p.Arg57Gly), gnomAD 17-75727410-A-G, REVEL 0.33, CADD 19.00
- R57R (p.Arg57Arg), gnomAD 17-75727412-G-A, CADD 8.47
- R59L (p.Arg59Leu), NCI-TCGA Cosmic COSV5233, REVEL 0.40, CADD 19.70, Variant assessed as somatic; moderate impact.
- R59P (p.Arg59Pro), 1000Genomes rs201532846, ExAC rs201532846, TOPMed rs201532846, gnomAD rs201532846, REVEL 0.26, CADD 14.80
- R59Q (p.Arg59Gln), rs201532846, NCI-TCGA Cosmic COSV5233, cosmic curated COSV52332, 1000Genomes rs201532846, REVEL 0.29, CADD 19.00, Variant assessed as somatic; moderate impact.
- R59W (p.Arg59Trp), rs544136973, ClinGen CA8768592, ClinVar RCV003739683, ExAC rs544136973, REVEL 0.39, CADD 23.10, Likely benign, not provided
- p.Arg59 Ala69del, rs1480399395, gnomAD 17-75727414-ACCGG, CADD 17.70
- R60C (p.Arg60Cys), rs550392338, ClinGen CA401038245, ClinVar RCV003560024, TOPMed rs550392338, REVEL 0.90, CADD 26.50, Uncertain significance, not provided
- R60H (p.Arg60His), rs746305033, ClinGen CA8768595, NCI-TCGA Cosmic COSV5233, cosmic curated COSV52333, REVEL 0.91, CADD 26.90, Uncertain significance, Epidermolysis bullosa, junctional 5A, intermediate; Junctional epidermolysis bul
- R60S (p.Arg60Ser), TOPMed rs550392338, gnomAD rs550392338, REVEL 0.89, CADD 24.70, Uncertain significance
- R60L (p.Arg60Leu), gnomAD 17-75727420-G-T, REVEL 0.92, CADD 26.60
- C61Y (p.Cys61Tyr), rs80338755, ClinGen CA341333, ClinVar RCV000015855, ClinVar RCV000413122, REVEL 0.96, CADD 26.00, Pathogenic/Likely pathogenic, Epidermolysis bullosa, junctional 5A, intermediate; Junctional epidermolysis bul
- C61F (p.Cys61Phe), gnomAD 17-75727423-G-T, REVEL 0.97, CADD 26.10
- C61* (p.Cys61Ter), gnomAD 17-75727424-C-A, CADD 34.00
- T63I (p.Thr63Ile), TOPMed rs1166211415, gnomAD rs1166211415, REVEL 0.39, CADD 22.10
- T63N (p.Thr63Asn), TOPMed rs1166211415, gnomAD rs1166211415, REVEL 0.40, CADD 22.20
- T63A (p.Thr63Ala), gnomAD 17-75727428-A-G, REVEL 0.40, CADD 22.00
- T63T (p.Thr63Thr), gnomAD 17-75727430-C-G, CADD 6.17
- A65E (p.Ala65Glu), ESP rs200966154, ExAC rs200966154, TOPMed rs200966154, gnomAD rs200966154, REVEL 0.23, CADD 0.52, Uncertain significance
- A65T (p.Ala65Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A65V (p.Ala65Val), rs200966154, ClinGen CA8768596, cosmic curated COSV52331, ClinVar RCV002956852, REVEL 0.11, CADD 11.80, Uncertain significance, ITGB4-related disorder; Epidermolysis bullosa, junctional 5A, intermediate; Junc
- A65A (p.Ala65Ala), rs372797886, gnomAD 17-75727436-G-A, CADD 0.27
- E66E (p.Glu66Glu), rs1015321334, gnomAD 17-75727439-G-A, CADD 8.89
- L67M (p.Leu67Met), TOPMed rs1199065722
- L67Q (p.Leu67Gln), gnomAD rs1372151872, REVEL 0.89, CADD 25.30
- L67R (p.Leu67Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- L67V (p.Leu67Val), gnomAD 17-75727440-C-G, REVEL 0.59, CADD 21.40
- A69V (p.Ala69Val), TOPMed rs1312234220, gnomAD rs1312234220, REVEL 0.31, CADD 20.60
- A69A (p.Ala69Ala), rs776953208, gnomAD 17-75727448-C-T, CADD 2.19
- A70E (p.Ala70Glu), ExAC rs747831589, TOPMed rs747831589, gnomAD rs747831589, REVEL 0.31, CADD 12.30
- A70T (p.Ala70Thr), rs569235037, NCI-TCGA Cosmic COSV5233, cosmic curated COSV52332, 1000Genomes rs569235037, REVEL 0.19, CADD 12.50, Variant assessed as somatic; moderate impact.
- A70V (p.Ala70Val), rs747831589, NCI-TCGA Cosmic COSV5232, cosmic curated COSV52325, ExAC rs747831589, REVEL 0.31, CADD 13.00, Uncertain significance, Inborn genetic diseases
- A70S (p.Ala70Ser), gnomAD 17-75727449-G-T, REVEL 0.11, CADD 9.53
- A70A (p.Ala70Ala), rs200500313, gnomAD 17-75727451-G-A, CADD 0.32
- G71C (p.Gly71Cys), gnomAD rs1226422448, REVEL 0.76, CADD 25.20
- G71A (p.Gly71Ala), gnomAD 17-75727450-CG-C, CADD 0.53
- G71D (p.Gly71Asp), gnomAD 17-75727453-G-A, REVEL 0.71, CADD 24.50
- C72Y (p.Cys72Tyr), NCI-TCGA TCGA novel, REVEL 0.85, CADD 25.10, Variant assessed as somatic; moderate impact.
- C72G (p.Cys72Gly), gnomAD 17-75727455-T-G, REVEL 0.84, CADD 24.80
- Q73* (p.Gln73Ter), rs1392939514, ClinGen CA401038444, ClinVar RCV003560025, ClinVar RCV004750389, CADD 33.00, Pathogenic
- R74Q (p.Arg74Gln), rs1233389477, TOPMed rs1233389477, gnomAD rs1233389477, REVEL 0.28, CADD 0.00, Variant assessed as somatic; moderate impact.
- R74W (p.Arg74Trp), rs772790459, ClinGen CA8768602, NCI-TCGA Cosmic COSV9956, cosmic curated COSV99564, REVEL 0.30, CADD 22.60, Uncertain significance, Inborn genetic diseases; not provided
- E75K (p.Glu75Lys), TOPMed rs2060745360, REVEL 0.26, CADD 14.20
- E75D (p.Glu75Asp), gnomAD 17-75727466-G-C, REVEL 0.15, CADD 12.70
- S76G (p.Ser76Gly), TOPMed rs1483602810, gnomAD rs1483602810, REVEL 0.26, CADD 18.00
- S76N (p.Ser76Asn), gnomAD rs1210526442, REVEL 0.30, CADD 17.30
Public ITGB4 analysis runs
- ITGB4 analysis run — ITGB4 (2,379 variants) — completed 2026-08-22